Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators.

Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Erratum in: Lancet. 2019 May 11;393(10184):1936.

PMID:
30995972
2.

Rituximab bioavailability in primary membranous nephropathy.

Boyer-Suavet S, Andreani M, Cremoni M, Brglez V, Benzaken S, Bernard G, Nachman P, Esnault V, Seitz-Polski B.

Nephrol Dial Transplant. 2019 Mar 30. pii: gfz041. doi: 10.1093/ndt/gfz041. [Epub ahead of print] No abstract available.

PMID:
30929012
3.

The OncoAge Consortium: Linking Aging and Oncology from Bench to Bedside and Back Again.

Hofman P, Ayache N, Barbry P, Barlaud M, Bel A, Blancou P, Checler F, Chevillard S, Cristofari G, Demory M, Esnault V, Falandry C, Gilson E, Guérin O, Glaichenhaus N, Guigay J, Ilié M, Mari B, Marquette CH, Paquis-Flucklinger V, Prate F, Saintigny P, Seitz-Polsky B, Skhiri T, Van Obberghen-Schilling E, Van Obberghen E, Yvan-Charvet L.

Cancers (Basel). 2019 Feb 21;11(2). pii: E250. doi: 10.3390/cancers11020250.

4.

Osmotic stress and mortality in elderly patients with kidney failure: a retrospective study.

Grangeon-Chapon C, Dodoi M, Esnault VL, Favre G.

Clin Interv Aging. 2019 Jan 30;14:225-229. doi: 10.2147/CIA.S158987. eCollection 2019.

5.

An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study).

Rémy P, Audard V, Natella PA, Pelle G, Dussol B, Leray-Moragues H, Vigneau C, Bouachi K, Dantal J, Vrigneaud L, Karras A, Pourcine F, Gatault P, Grimbert P, Ait Sahlia N, Moktefi A, Daugas E, Rigothier C, Bastuji-Garin S, Sahali D; MSN Trial Investigators.

Kidney Int. 2018 Dec;94(6):1217-1226. doi: 10.1016/j.kint.2018.07.021. Epub 2018 Oct 29.

PMID:
30385039
6.

Longitudinal assessment of renal function in native kidney after bariatric surgery.

Favre G, Schiavo L, Lemoine S, Esnault VLM, Iannelli A.

Surg Obes Relat Dis. 2018 Sep;14(9):1411-1418. doi: 10.1016/j.soard.2018.05.013. Epub 2018 May 24. Review.

PMID:
30077663
7.

[Glomerular diseases in brief].

Andreani M, Esnault V.

Rev Prat. 2018 Jan;68(1):e13-e14. French. No abstract available.

PMID:
30840405
8.

[Glomerular nephropathy].

Andreani M, Esnault V.

Rev Prat. 2018 Jan;68(1):e3-e12. French. No abstract available.

PMID:
30840404
9.

Phospholipase A2 Receptor 1 Epitope Spreading at Baseline Predicts Reduced Likelihood of Remission of Membranous Nephropathy.

Seitz-Polski B, Debiec H, Rousseau A, Dahan K, Zaghrini C, Payré C, Esnault VLM, Lambeau G, Ronco P.

J Am Soc Nephrol. 2018 Feb;29(2):401-408. doi: 10.1681/ASN.2017070734. Epub 2017 Nov 7.

10.

Determinants associated with the correction of glomerular hyper-filtration one year after bariatric surgery.

Favre G, Anty R, Canivet C, Clément G, Ben-Amor I, Tran A, Gugenheim J, Gual P, Esnault VLM, Iannelli A.

Surg Obes Relat Dis. 2017 Oct;13(10):1760-1766. doi: 10.1016/j.soard.2017.07.018. Epub 2017 Jul 19.

PMID:
28869167
11.

[Membranous nephropathy: Pathophysiology and natural history].

Seitz-Polski B, Lambeau G, Esnault V.

Nephrol Ther. 2017 Apr;13 Suppl 1:S75-S81. doi: 10.1016/j.nephro.2017.01.012. Review. French.

PMID:
28577747
12.

Perirenal fat thickness measured with computed tomography is a reliable estimate of perirenal fat mass.

Favre G, Grangeon-Chapon C, Raffaelli C, François-Chalmin F, Iannelli A, Esnault V.

PLoS One. 2017 Apr 19;12(4):e0175561. doi: 10.1371/journal.pone.0175561. eCollection 2017.

13.

Vitamin E-Coated and Heparin-Coated Dialyzer Membranes for Heparin-Free Hemodialysis: A Multicenter, Randomized, Crossover Trial.

Islam MS, Hassan ZA, Chalmin F, Vido S, Berrada M, Verhelst D, Donnadieu P, Moranne O, Esnault VL.

Am J Kidney Dis. 2016 Nov;68(5):752-762. doi: 10.1053/j.ajkd.2016.05.013. Epub 2016 Jun 23.

PMID:
27344212
14.

Multiphasic effects of blood pressure on survival in hemodialysis patients.

Hannedouche T, Roth H, Krummel T, London GM, Jean G, Bouchet JL, Drüeke TB, Fouque D; French Observatory.

Kidney Int. 2016 Sep;90(3):674-84. doi: 10.1016/j.kint.2016.05.025.

15.

Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.

Seitz-Polski B, Dolla G, Payré C, Girard CA, Polidori J, Zorzi K, Birgy-Barelli E, Jullien P, Courivaud C, Krummel T, Benzaken S, Bernard G, Burtey S, Mariat C, Esnault VL, Lambeau G.

J Am Soc Nephrol. 2016 May;27(5):1517-33. doi: 10.1681/ASN.2014111061. Epub 2015 Nov 13.

16.

Cross-reactivity of anti-PLA2R1 autoantibodies to rabbit and mouse PLA2R1 antigens and development of two novel ELISAs with different diagnostic performances in idiopathic membranous nephropathy.

Seitz-Polski B, Dolla G, Payré C, Tomas NM, Lochouarn M, Jeammet L, Mariat C, Krummel T, Burtey S, Courivaud C, Schlumberger W, Zorzi K, Benzaken S, Bernard G, Esnault VL, Lambeau G.

Biochimie. 2015 Nov;118:104-15. doi: 10.1016/j.biochi.2015.08.007. Epub 2015 Aug 19.

PMID:
26296473
17.

Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial.

Azizi M, Sapoval M, Gosse P, Monge M, Bobrie G, Delsart P, Midulla M, Mounier-Véhier C, Courand PY, Lantelme P, Denolle T, Dourmap-Collas C, Trillaud H, Pereira H, Plouin PF, Chatellier G; Renal Denervation for Hypertension (DENERHTN) investigators.

Lancet. 2015 May 16;385(9981):1957-65. doi: 10.1016/S0140-6736(14)61942-5. Epub 2015 Jan 26.

PMID:
25631070
18.

Modulation of glucose metabolism by the renin-angiotensin-aldosterone system.

Favre GA, Esnault VL, Van Obberghen E.

Am J Physiol Endocrinol Metab. 2015 Mar 15;308(6):E435-49. doi: 10.1152/ajpendo.00391.2014. Epub 2015 Jan 6. Review.

19.

Constitutive activation of the renin-angiotensin system reduces visceral fat and improves glucose tolerance in mice.

Favre GA, Lebrun P, Lopez P, Butori C, Hofman P, Esnault VL, Van Obberghen E.

J Renin Angiotensin Aldosterone Syst. 2014 Dec;15(4):396-409. doi: 10.1177/1470320314537695. Epub 2014 Nov 4.

PMID:
25371094
20.

Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients.

Seitz-Polski B, Payré C, Ambrosetti D, Albano L, Cassuto-Viguier E, Berguignat M, Jeribi A, Thouret MC, Bernard G, Benzaken S, Lambeau G, Esnault VL.

Nephrol Dial Transplant. 2014 Dec;29(12):2334-42. doi: 10.1093/ndt/gfu252. Epub 2014 Jul 25.

PMID:
25063424

Supplemental Content

Loading ...
Support Center